Reference : Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's...
Scientific journals : Article
Life sciences : Genetics & genetic processes
http://hdl.handle.net/10993/17237
Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's disease: study protocol for a randomized controlled trial.
English
Weiss, Daniel [> >]
Wachter, Tobias [> >]
Meisner, Christoph [> >]
Fritz, Melanie [> >]
Gharabaghi, Alireza [> >]
Plewnia, Christian [> >]
Breit, Sorin [> >]
Krüger, Rejko mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
2011
Trials
12
222
Yes (verified by ORBilu)
1745-6215
1745-6215
England
[en] Adolescent ; Adult ; Aged ; Aged, 80 and over ; Clinical Protocols ; Cross-Over Studies ; Data Interpretation, Statistical ; Deep Brain Stimulation/methods ; Double-Blind Method ; Gait ; Humans ; Middle Aged ; Outcome Assessment (Health Care) ; Parkinson Disease/therapy ; Sample Size ; Substantia Nigra/physiology ; Subthalamic Nucleus/physiology
[en] BACKGROUND: Severe gait disturbances in idiopathic Parkinson's disease (PD) are observed in up to 80% of all patients in advanced disease stages with important impact on quality of life. There is an unmet need for further symptomatic therapeutic strategies, particularly as gait disturbances generally respond unfavourably to dopaminergic medication and conventional deep brain stimulation of the subthalamic nucleus in advanced disease stages. Recent pathophysiological research pointed to nigro-pontine networks entrained to locomotor integration. Stimulation of the pedunculopontine nucleus is currently under investigation, however, hitherto remains controversial. The substantia nigra pars reticulata (SNr)--entrained into integrative locomotor networks--is pathologically overactive in PD. High-frequent stimulation of the substantia nigra pars reticulata preferentially modulated axial symptoms and therefore is suggested as a novel therapeutic candidate target for neuromodulation of refractory gait disturbances in PD. METHODS: 12 patients with idiopathic Parkinson's disease and refractory gait disturbances under best individual subthalamic nucleus stimulation and dopaminergic medication will be enroled into this double-blind 2 x 2 cross-over clinical trial. The treatment consists of two different stimulation settings using (i) conventional stimulation of the subthalamic nucleus [STNmono] and (ii) combined stimulation of distant electrode contacts located in the subthalamic nucleus and caudal border zone of STN and substantia nigra pars reticulata [STN+SNr]. The primary outcome measure is the change of the cumulative 'axial score' (UPDRS II items '13-15' and UPRDS III items '27-31') at three weeks of constant stimulation in either condition. Secondary outcome measures include specific scores on freezing of gait, balance function, quality of life, non-motor symptoms, and neuropsychiatric symptoms. The aim of the present trial is to investigate the efficacy and safety of a three week constant combined stimulation on [STN+SNr] compared to [STNmono]. The results will clarify, whether stimulation on nigral contacts additional to subthalamic stimulation will improve therapeutic response of otherwise refractory gait disturbances in PD. TRIAL REGISTRATION: The trial was registered with the clinical trials register of http://www.clinicaltrials.gov (NCT01355835).
Luxembourg Centre for Systems Biomedicine (LCSB): Clinical & Experimental Neuroscience (Krüger Group)
http://hdl.handle.net/10993/17237
10.1186/1745-6215-12-222

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Weiss2011e.pdfPublisher postprint276.46 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.